» Articles » PMID: 31244590

Broad Lipidomic and Transcriptional Changes of Prophylactic PEA Administration in Adult Mice

Overview
Journal Front Neurosci
Date 2019 Jun 28
PMID 31244590
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Beside diverse therapeutic properties of palmitoylethanolamide (PEA) including: neuroprotection, inflammation and pain alleviation, prophylactic effects have also been reported in animal models of infections, inflammation, and neurological diseases. The availability of PEA as (ultra)micronized nutraceutical formulations with reportedly no side effects, renders it accordingly an appealing candidate in human preventive care, such as in population at high risk of disease development or for healthy aging. PEA's mode of action is multi-facetted. Consensus exists that PEA's effects are primarily modulated by the peroxisome proliferator-activated receptor alpha (PPARα) and that PEA-activated PPARα has a pleiotropic effect on lipid metabolism, inflammation gene networks, and host defense mechanisms. Yet, an exhaustive view of how the prophylactic PEA administration changes the lipid signaling in brain and periphery, thereby eliciting a beneficial response to various negative stimuli remains still elusive. We therefore, undertook a broad lipidomic and transcriptomic study in brain and spleen of adult mice to unravel the positive molecular phenotype rendered by prophylactic PEA. We applied a tissue lipidomic and transcriptomic approach based on simultaneous extraction and subsequent targeted liquid chromatography-multiple reaction monitoring (LC-MRM) and mRNA analysis by qPCR, respectively. We targeted lipids of COX-, LOX- and CYP450 pathways, respectively, membrane phospholipids, lipid products of cPLA, and free fatty acids, along with various genes involved in their biosynthesis and function. Additionally, plasma lipidomics was applied to reveal circulatory consequences and/or reflection of PEA's action. We found broad, distinct, and several previously unknown tissue transcriptional regulations of inflammatory pathways. In hippocampus also a PEA-induced transcriptional regulation of neuronal activity and excitability was evidenced. A massive downregulation of membrane lipid levels in the splenic tissue of the immune system with a consequent shift towards pro-resolving lipid environment was also detected. Plasma lipid pattern reflected to a large extent the hippocampal and splenic lipidome changes, highlighting the value of plasma lipidomics to monitor effects of nutraceutical PEA administration. Altogether, these findings contribute new insights into PEA's molecular mechanism and helps answering the questions, how PEA prepares the body for insults and what are the "good lipids" that underlie this action.

Citing Articles

Integrated cellular 4D-TIMS lipidomics and transcriptomics for characterization of anti-inflammatory and anti-atherosclerotic phenotype of MyD88-KO macrophages.

Del Barrio Calvo C, Bindila L Front Cell Dev Biol. 2024; 12:1450971.

PMID: 39247623 PMC: 11377276. DOI: 10.3389/fcell.2024.1450971.


ERK1/2-CEBPB Axis-Regulated hBD1 Enhances Anti-Tuberculosis Capacity in Alveolar Type II Epithelial Cells.

Chen Y, Han Z, Zhang S, Liu H, Wang K, Liu J Int J Mol Sci. 2024; 25(4).

PMID: 38397085 PMC: 10889425. DOI: 10.3390/ijms25042408.


Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.

Sousa N, Geiss C, Bindila L, Lieberwirth I, Kim E, Regnier-Vigouroux A BMC Cancer. 2023; 23(1):762.

PMID: 37587449 PMC: 10433583. DOI: 10.1186/s12885-023-11271-w.


Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study.

Masnikosa R, Piric D, Post J, Cvetkovic Z, Petrovic S, Paunovic M Cancers (Basel). 2023; 15(14).

PMID: 37509314 PMC: 10377844. DOI: 10.3390/cancers15143653.


Four-dimensional trapped ion mobility spectrometry lipidomics for high throughput clinical profiling of human blood samples.

Lerner R, Baker D, Schwitter C, Neuhaus S, Hauptmann T, Post J Nat Commun. 2023; 14(1):937.

PMID: 36806650 PMC: 9941096. DOI: 10.1038/s41467-023-36520-1.


References
1.
Binder D, Croll S, Gall C, Scharfman H . BDNF and epilepsy: too much of a good thing?. Trends Neurosci. 2001; 24(1):47-53. DOI: 10.1016/s0166-2236(00)01682-9. View

2.
Lambert D, Vandevoorde S, Diependaele G, Govaerts S, Robert A . Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia. 2001; 42(3):321-7. DOI: 10.1046/j.1528-1157.2001.41499.x. View

3.
Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M . Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001; 358(Pt 1):249-55. PMC: 1222054. DOI: 10.1042/0264-6021:3580249. View

4.
Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G . Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002; 135(1):181-7. PMC: 1573125. DOI: 10.1038/sj.bjp.0704466. View

5.
Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View